Congenital Hyperinsulinism clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

    open to eligible people ages 2 years and up

    This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.

    Los Angeles, California and other locations

Our lead scientists for Congenital Hyperinsulinism research studies include .

Last updated: